I-Wei Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
I-Wei Lin has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ken-Hong Lim
Division of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei City, Taiwan
1 shared publication - Meng-Ta Sung
Division of Hematology and Oncology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
1 shared publication Yen-Chang Huang
Division of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei City, Taiwan
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Hematology
- Vol. 2025 (1)
Eltrombopag‐Induced Cerebral Venous Thrombosis: A Case Report and Literature Review
Immune thrombocytopenia purpura (ITP) is initially treated with steroids, but TPO‐RAs such as eltrombopag are used for chronic cases. Though effective, eltrombopag has been linked to thromboembolic events, with cerebral venous thrombosis (CVT) being a rare complication. A 20‐year‐old woman with ITP developed severe headaches, nausea, and vomiting five days after starting eltrombopag. CT scans revealed a dense clot in the right transverse sinus, indicating CVT. Lab data showed elevated platelet counts and D‐dimer levels. MRV confirmed CVT, leading to the discontinuation of eltrombopag and initiation of anticoagulant therapy. Recurring thrombocytopenia necessitated further treatment adjustments, including rituximab and cyclosporine, resulting in improved platelet counts and CVT resolution. This case highlighted that CVT is a serious but rare side effect of eltrombopag in ITP patients. Early detection, prompt anticoagulation, and cautious TPO‐RA management are crucial for preventing thromboembolic events.
- 1 January 2025
- Published by Wiley in Case Reports in Hematology
- Vol. 2025 (1)
Open AccessEltrombopag‐Induced Cerebral Venous Thrombosis: A Case Report and Literature Review
Immune thrombocytopenia purpura (ITP) is initially treated with steroids, but TPO‐RAs such as eltrombopag are used for chronic cases. Though effective, eltrombopag has been linked to thromboembolic events, with cerebral venous thrombosis (CVT) being a rare complication. A 20‐year‐old woman with ITP developed severe headaches, nausea, and vomiting five days after starting eltrombopag. CT scans revealed a dense clot in the right transverse sinus, indicating CVT. Lab data showed elevated platelet counts and D‐dimer levels. MRV confirmed CVT, leading to the discontinuation of eltrombopag and initiation of anticoagulant therapy. Recurring thrombocytopenia necessitated further treatment adjustments, including rituximab and cyclosporine, resulting in improved platelet counts and CVT resolution. This case highlighted that CVT is a serious but rare side effect of eltrombopag in ITP patients. Early detection, prompt anticoagulation, and cautious TPO‐RA management are crucial for preventing thromboembolic events.